Skip to main content
Clinical Trials/NCT01041469
NCT01041469CompletedNot Applicable

Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome

Institut Jerome Lejeune2 sites in 1 country72 target enrollmentStarted: November 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
72
Locations
2
Primary Endpoint
Auto-antibodies dosage

Study Overview

Brief Summary

The purpose of the study is to identify biological data linked to auto immune abnormalities associated with Down Syndrome.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
8 Years to 36 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Free and complete trisomy 21
  • aged between 8 and 36 years
  • biological or clinical signs of auto-immune disorder (group 1)
  • no sign of auto-immune disorder (group 2)

Exclusion Criteria

  • any antimitotic or immune depressing treatment during the last 6 months
  • Current infectious disease
  • Corticosteroid therapy in the last 3 weeks
  • pregnancy

Outcomes

Primary Outcomes

Auto-antibodies dosage

Time Frame: at enrolment

specific lymphocytes populations count

Time Frame: at enrolment

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials